MedTrace Logo

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

NCT00125736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2018-10-29

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy and safety of combination use of E0671 and Rabeprazole Sodium in patients with gastric ulcer.

Conditions

  • Stomach Ulcer

Interventions

DRUG

E0671

One 50 mg capsule is orally administered three times daily (150 mg/day)

DRUG

rabeprazole sodium

One 10mg tablet is administered orally each day

DRUG

E0671 placebo

One 50 mg capsule is orally administered three times daily (150 mg/day)

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Toshihisa Arai · GI Group. Post-Marketing Clinical Research Dept., Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-01
Primary Completion
2007-04-19
Completion
2007-04-19

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125736 on ClinicalTrials.gov